Saturday, August 23, 2025

Game-Changing Solution for Heart Inflammation? | David Elsley – Cardiol Therapeutics

FULL DISCLOSURE: This is sponsored content for Cardiol Therapeutics.

In this interview with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), we explore the company’s innovative approach to treating inflammatory heart conditions. Cardiol’s lead product, CardiolRxâ„¢, is an oral therapy targeting recurrent pericarditis and acute myocarditis – debilitating heart conditions that currently lack effective treatment options.

Elsley discusses their promising Phase 2 trial results presented at the American Heart Association, showing sustained pain reduction and decreased inflammation markers. He explains how their ultra-high-dose, pharmaceutically manufactured formulation differs from standard CBD products, and outlines key upcoming catalysts including Phase 2/3 trial results expected in early 2025 that could accelerate their path to market under FDA’s orphan drug designation.

READ: Cardiol To Advance CardiolRx To Phase III Trial Following Positive Results


FULL DISCLOSURE: Cardiol Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is long the equity of Cardiol Therapeutics. The author has been compensated to cover Cardiol Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

A Medical Breakthrough the Market Overlooked | David Elsley – Cardiol Therapeutics

Why Grade Beats Size in Silver Mining | Frank Basa – Nord Precious Metals

Are Investors Missing the Start of the Next Commodity Supercycle? | Morgan Lekstrom – NexMetals

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

Cardiol To Advance CardiolRx To Phase III Trial Following Positive Results

Cardiol Therapeutics (TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx,...
Tuesday, November 19, 2024, 08:19:00 AM

Cardiol Enters Into Supply Agreement With Shoppers Drug Mart

Cardiol Therapeutics Inc. (TSX: CRDL) has entered into a supplier agreement with Medical Cannabis by...

Wednesday, March 18, 2020, 03:27:03 PM

Cardiol Therapeutics Announces US Listing

Cardiol Therapeutics (TSX: CRDL; OTCMKTS: CRTPF) announced this morning that it has qualified to trade...

Thursday, May 30, 2019, 09:43:44 AM

A Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David Elsley – Cardiol Therapeutics

Discover the major breakthrough at Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) as CEO David Elsley...
Saturday, April 26, 2025, 11:38:00 AM

The Deep Dive Initiates Coverage on Cardiol Therapeutics

With a heavy focus on cannabinoids, Cardiol Therapeutics (TSX: CRDL) is not your typical cannabis...

Monday, April 29, 2019, 07:15:29 AM